Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 1.00 |
| ▸ | MEN1 | O00255 | 4/20 | 1.00 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.43 |
| ▸ | LTB4R | Q15722 | 2/20 | 0.43 |
| ▸ | LTB4R2 | Q9NPC1 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | KLK7 | P49862 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | FYN | P06241 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30078294 | 1.00 | KMT2A (1.00) | KMT2AMEN1GAAMAPTMAPK1 | |
| SCHEMBL5653865 | 0.91 | MEN1 (0.84) | KMT2AMEN1GAAMAPTMAPK1 | |
| SCHEMBL1168933 | 0.90 | MEN1 (0.82) | KMT2AMEN1GAAMAPTMAPK1 | |
| SCHEMBL5651574 | 0.90 | MEN1 (0.82) | KMT2AMEN1GAAMAPTMAPK1 | |
| SCHEMBL1168112 | 0.89 | MEN1 (0.80) | KMT2AMEN1GAAMAPTMAPK1 | |
| SCHEMBL1168646 | 0.89 | MEN1 (0.80) | KMT2AMEN1GAAMAPTMAPK1 | |
| SCHEMBL1167512 | 0.89 | MEN1 (0.80) | KMT2AMEN1GAAMAPTMAPK1 | |
| SCHEMBL1168931 | 0.89 | MEN1 (0.80) | KMT2AMEN1GAAMAPTMAPK1 | |
| SCHEMBL12338602 | 0.88 | KMT2A (0.78) | KMT2AMEN1GAAMAPTMAPK1 | |
| SCHEMBL1168254 | 0.86 | MEN1 (0.76) | KMT2AMEN1GAAMAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7250432-B2 | Pharmaceutical compositions of diaryl-isoxazole derivatives for the prevention and treatment of cancers | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2007-07-31 | — | — | US | claimed |
| US-20050131036-A1 | Pharmaceutical compositions of diaryl-isoxazole derivatives for the prevention and treatment of cancers | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2005-06-16 | — | — | US | claimed |
| US-9717792-B2 | Combination therapy for cancer using HSP27 inhibitor and EGFR tyrosine kinase inhibitors or anti-folates | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2017-08-01 | — | — | US | disclosed |
| US-9326993-B2 | Treatment of pulmonary and pleural fibrosis using HSP27 inhibitors | ONCOGENEX TECHNOLOGIES INC. (CA) | 2016-05-03 | — | — | US | disclosed |
| US-9090603-B2 | Compounds for the treatment of proliferative disorders | SYNTA PHARMACEUTICALS CORPORATION (US) | 2015-07-28 | — | — | US | disclosed |
| US-9090603-B2 | Compounds for the treatment of proliferative disorders | SYNTA PHARMACEUTICALS CORPORATION (US) | 2015-07-28 | — | — | US | disclosed |
| US-20150126584-A1 | Treatment of Pulmonary and Pleural Fibrosis Using HSP27 Inhibitors | ONCOGENEX TECHNOLOGIES INC. (CA) | 2015-05-07 | — | — | US | disclosed |
| US-8987223-B2 | Treatment of pulmonary and pleural fibrosis using HSP27 inhibitors | ONCOGENEX TECHNOLOGIES INC. (CA) | 2015-03-24 | — | — | US | disclosed |
| US-20150050285-A1 | Combination Therapy for Cancer Using HSP27 Inhibitor and EGFR Tyrosine Kinase Inhibitors or Anti-Folates | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2015-02-19 | — | — | US | disclosed |
| EP-2809325-A1 | COMBINATION THERAPY FOR CANCER USING HSP27 INHIBITOR AND EGFR TYROSINE KINASE INHIBITORS OR ANTI-FOLATES | The University of British Columbia (CA) | 2014-12-10 | — | — | EP | disclosed |
| US-20140045795-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | SYNTA PHARMACEUTICALS CORPORATION (US) | 2014-02-13 | — | — | US | disclosed |
| US-20090092566-A1 | SELF-TANNING COSMETIC COMPOSITIONS AND METHODS | ELC MANAGEMENT LLC | 2009-04-09 | — | — | US | disclosed |
| EP-1919882-A2 | ISOXAZOLE COMBRETASTATIN DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | Synta Pharmaceuticals Corporation (US) | 2008-05-14 | — | — | EP | disclosed |
| WO-2008033449-A2 | COMPOUNDS FOR THE TREATMENT OF ANGIOGENESIS | SYNTA PHARMACEUTICALS CORP. (US) | 2008-03-20 | — | — | WO | disclosed |
| US-7250432-B2 | Pharmaceutical compositions of diaryl-isoxazole derivatives for the prevention and treatment of cancers | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2007-07-31 | — | — | US | disclosed |
| US-7250432-B2 | Pharmaceutical compositions of diaryl-isoxazole derivatives for the prevention and treatment of cancers | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2007-07-31 | — | — | US | disclosed |
| WO-2006126751-A1 | NEW DIARYL-ISOXAZOLE DERIVATIVES, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME FOR THE PREVENTION AND THE TREATMENT OF CANCERS | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2006-11-30 | — | — | WO | disclosed |
| US-20060217389-A1 | Compounds for the treatment of proliferative disorders | SYNTA PHARMACEUTICALS CORP. | 2006-09-28 | — | — | US | disclosed |
| WO-2006089177-A2 | ISOXAZOLE COMBRETASTIN DERIVATIVES FOR THE TREATMENT OF DISORDERS | SYNTA PHARMACEUTICALS CORP. (US) | 2006-08-24 | — | — | WO | disclosed |
| US-20050131036-A1 | Pharmaceutical compositions of diaryl-isoxazole derivatives for the prevention and treatment of cancers | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2005-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140045795-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | RB1, MKI67, MAPRE1 | KMT2A 2808/4885MEN1 1571/4885GAA 597/4885 |
| US-20090092566-A1 | SELF-TANNING COSMETIC COMPOSITIONS AND METHODS | TNNI3K, CHEK1, CHEK2 | KMT2A 1521/4885MEN1 2760/4885GAA 780/4885 |
| US-20050131036-A1 | Pharmaceutical compositions of diaryl-isoxazole derivatives for the prevention and treatment of cancers | UACA, SQLE, ALDH1A2 | KMT2A 4307/4885MEN1 3914/4885GAA 4206/4885 |
| US-20060217389-A1 | Compounds for the treatment of proliferative disorders | RB1, MKI67, MAPRE1 | KMT2A 2808/4885MEN1 1571/4885GAA 597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.